Bectumomab

DB04962ExperimentalProtein Based Therapies

Bectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it's used to treat non-Hodgkin's lymphoma. It has a radioisotope, technetium (99m TC) which it's added.

Mechanism: Using bectumomab, a mouse-derived monoclonal antibody labeled with technetium-99m (Tc-99m), a widely available, inexpensive radioisotope, medical professionals can determine through nuclear imaging the extent of CD22-expressing lymphomas.
Curator reviewed
Primary indication: Investigated for use/treatment in lymphoma (non-hodgkin's).Curator reviewed

Resolves to

Compound

CAS158318-63-9

Targets

P20273CD22

What you can answer from here — as of October 01, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bectumomab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account